Evidence map›Paper›PMID 35385421›Full record

ArticleJournal of the Chinese Medical Association : JCMA2022

Autophagy reprogramming stem cell pluripotency and multiple-lineage differentiation.

Yi-Ping Yang, Wei-Yi Lai, Tzu-Wei Lin, Yi-Ying Lin, Yueh Chien, Yi-Ching Tsai, Hsiao-Yun Tai, Chia-Lin Wang, Yung-Yang Liu, Pin-I Huang and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of the Chinese Medical Association : JCMA, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Yi-Ping YangDepartment of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Wei-Yi LaiDepartment of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Tzu-Wei LinDepartment of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Yi-Ying LinDepartment of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Yueh ChienDepartment of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Yi-Ching TsaiDepartment of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Hsiao-Yun TaiDepartment of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Chia-Lin WangDepartment of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Yung-Yang LiuSchool of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
Pin-I HuangSchool of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
Yi-Wei ChenSchool of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
Wen-Liang LoInstitute of Oral Biology, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
Chien-Ying WangSchool of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
Taipei Veterans General Hospital · TWNational Yang Ming Chiao Tung University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The cellular process responsible for the degradation of cytosolic proteins and subcellular organelles in lysosomes was termed "autophagy." This process occurs at a basal level in most tissues as part of tissue homeostasis that redounds to the regular turnover of components inside cytoplasm. The breakthrough in the autophagy field is the identification of key players in the autophagy pathway, compounded under the name "autophagy-related genes" (ATG) encoding for autophagy effector proteins. Generally, the function of autophagy can be classified into two divisions: intracellular clearance of defective macromolecules and organelles and generation of degradation products. Therapeutic strategies using stem cell-based approach come as a promising therapy and develop rapidly recently as stem cells have high self-renewability and differentiation capability as known as mesenchymal stem cells (MSCs). They are defined as adherent fibroblast-like population with the abilities to self-renew and multi-lineage differentiate into osteogenic, adipogenic, and chondrogenic lineage cells. To date, they are the most extensively applied adult stem cells in clinical trials. The properties of MSCs, such as immunomodulation, neuroprotection, and tissue repair pertaining to cell differentiation, processes to replace lost, or damaged cells, for aiding cell repair and revival. Autophagy has been viewed as a remarkable mechanism for maintaining homeostasis, ensuring the adequate function and survival of long-lived stem cells. In addition, authophagy also plays a remarkable role in protecting stem cells against cellular stress when the stem cell regenerative capacity is harmed in aging and cellular degeneration. Understanding the under-explored mechanisms of MSC actions and expanding the spectrum of their clinical applications may improve the utility of the MSC-based therapeutic approach in the future.

Indexed as

Mesenchymal Stem CellsStem CellsAutophagyCell DifferentiationOsteogenesis

Identifiers

PMID35385421
PMCPMC12755587
OpenAlexW4225784209

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.